Majesco


Cmp :821

Accumulate :800-825

SL : 735

T-1000

INDSWIFT LABS

UNDERVALUED API STOCK

CMP - 42.95

MARKET CAP - 250cr

FV - 10

ACCMULATION ZONE - ON ALL DIPS BWT 35 TO 43 IN SIP

52wk High Low - 47.50/15

BOOK VALUE - 108

TEST LEVELS # 75/90/100++

INDSWIFT LAB IS PURE API PLAYER WITH GOOD PORTFOLIO OF APIS.IT PLANT IS SPREAD IN 33 ACERS

FY21 WOULD BE GOOD YEAR FOR COMPANY IN TERMS OF GROWTH & PROFITS

FY21 EXPECTED EBIDTA 240Cr++

COMPANY SUPPLIES 7 TO 8 PRODUCTS TO U.S MARKETS.U.S IS SIGINIFICANT MARKET FOR ITS PRODUCTS.

14% OF ITS TOTAL TURNOVER COME FROM U.S MARKETS

RECENTLY COMPANY LAUNCHED FEXOFENADINE AN ANTI HISTAMINE DRUG USED IN TREATMENT OF SEASONAL ALLEGRIC

Disc - Consult your financial advisor before investing or taking any position based on above article.

AS EXPECTED

NIFTY TAKING 200 DMA SUPPORT & BOUNCING BACK

TODAY CAN BE BULL DAYS

NIFTY 120 ++ 💚💚

GODREJ CONSUMER

YEST LOWS 670

CAME IN ACCMULATION ZONE

GETTING READY & CHARGED FOR BIG UPMOVE

FMCG CAN OUTPERFORM & SHOW RESILENCE EVEN IN DOWN MARKET

GOVERNMENT CAN ANNOUNCE SOME STIMULUS PACKAGE IN UPCOMING WEEK

LETS HOPE FOR THAT

MKTS CAN SEE SOME MORE POSITIVE MOVES ON THAT NOTE

BEPL

BLASTING AGAIN

UP 14% 💚💚

73

UPDATE

OUR INVESTMENT PICK

GRANULES

HIT NEW ALL TIME HIGH

395

NIFTY

+200

💚💚

THIS IS JUST BOUNCE CAN EXTEND TILL 11200/11250

ONLY ON CLOSE ABOVE 11300 SHORT TREM TREND WOULD TURN POSITIVE FOR BULLISH MODE

https://wealthcreatures.com/2020/03/25/visaka-inds-can-past-glory-of-stock-return-back-in-next-5-year-again-only-time-would-tell/

🎯VISAKA INDS GIVEN @ 94 HITS 386 IN JUST 5 MONTHS ALREADY 4X DONE

🎯NOW AGAIN AVAILABLE @ 294.

🎯ONE SHOULD LOOK FORWARD TO ADD ON DIPS IN SIP FOR INVESTMENT

🎯STRONG SUPPORT @ 265/240

🎯CURRENT DIVIDEND YIELD IS ATTRACTIVE @5.09%

🎯FY21 EXPECTED EPS # 45++

🎯STOCK TRADING AT PE OF JUST 6.5

🎯TRY ADDING NEAR SUPPORT LEVELS.

🎯EXPECTING GOOD Q2 NUMBERS ANS FY22 CAN BE A BETTER YEAR AND CAN BE RERATED SOON IN NEXT 3 TO 6 MONTHS

EXPECTING THIS TO BE 5×/8×/10× In LONGTERM.

IOL CHEMICALS & PHARMA :

IN AGM On 26th SEPT'20
Mr. Vijay Garg mentioned that the reason for revenue shortage in Q1 was due to shutdown of plant for 2 weeks due to lockdown.

Now management is confident of posting better results in Q2 FY21 and rest of the FY which will cover 25%-30% growth. Ibuprofen price remains stable at USD 15-20. IOL avg price in market is USD 16.

Regarding CAPEX they plan for 150-250 Crore every year from internal accruals.Mr. Vijay Garg has answered all the queries of investors in detail without missing any single query. Q&A session lasted for 45 mins which shows how much IOL has gained investor attention now.

Also revenue expected from Metformin is 150-200 crores every year. Ibuprofen demand is more than supply of all companies as per Vijay Garg. As per Vijay Garg, Q2 results will be announced in 30-45 days. All eyes now on Q2 results and con calls.
CARE credit rating is also stable.

Selling too early just because STOCK has run up too much too fast.

Till there is a visibility of business potential and company growth path, one should ride the growth as maximum as possible.

BANK NIFTY RACING

+350

MORATORIUM DECISION COMING @10 AM

IF POSITIVE BANKS WLD BLAST MORE

MASTEK GETTING READY FOR NEW ALL TIME HIGH VERY SOON